Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#101 / 200 Total
AGAE - Allied Gaming & Entertainment Inc - Stock Price Chart
TickerAGAE [NASD]
CompanyAllied Gaming & Entertainment Inc
CountryUSA
IndustryEntertainment
Market Cap65.09MEPS (ttm)-0.09
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y48.39%
P/S7.36EPS next 5Y-
P/B0.78EPS Q/Q12.42%
Dividend-Sales Q/Q99.35%
Insider Own57.71%Inst Own2.71%
Insider Trans6.99%Inst Trans-4.72%
Short Float1.18%EarningsMar 27/a
Analyst Recom1.00Target Price4.25
Avg Volume99.23K52W Range0.61 - 1.57
Allied Gaming & Entertainment, Inc. operates as an experiential entertainment company, which engages in the creation of esports venues and live events for both video games and poker. The company was founded in 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Choi Roy10% OwnerJul 10 '24Buy1.4968,331101,8133,080,153Jul 11 09:39 PM
Choi Roy10% OwnerJul 09 '24Buy1.47140,000205,8003,011,822Jul 11 09:39 PM
Choi Roy10% OwnerJul 03 '24Buy1.2645,00056,7002,871,822Jul 03 09:48 PM
Choi Roy10% OwnerJul 02 '24Buy1.27235,000298,4502,826,822Jul 03 09:48 PM
Choi Roy10% OwnerJul 01 '24Buy1.2780,000101,6002,591,822Jul 03 09:48 PM
ELVN - Enliven Therapeutics Inc - Stock Price Chart
TickerELVN [NASD, RUT]
CompanyEnliven Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.28BEPS (ttm)-1.93
P/E-EPS this Y-12.60%
Forward P/E-EPS next Y-22.31%
PEG-EPS past 5Y5.16%
P/S-EPS next 5Y-
P/B4.02EPS Q/Q32.00%
Dividend-Sales Q/Q-
Insider Own42.58%Inst Own57.24%
Insider Trans-16.13%Inst Trans-9.18%
Short Float19.42%EarningsMay 14/a
Analyst Recom1.20Target Price34.00
Avg Volume324.73K52W Range9.80 - 26.00
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel AnishCHIEF OPERATING OFFICERJul 16 '24Sale25.011,54738,692344,027Jul 16 05:37 PM
Patel AnishCHIEF OPERATING OFFICERJul 15 '24Sale25.0530,978776,039345,574Jul 16 05:37 PM
Heyman Richard A.DirectorJul 15 '24Sale24.801,27031,497133,345Jul 17 07:25 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERJul 12 '24Option Exercise2.483,0007,4403,000Jul 16 05:34 PM
Patel AnishCHIEF OPERATING OFFICERJul 12 '24Sale25.0717,475438,095376,552Jul 16 05:37 PM
CBAN - Colony Bankcorp, Inc. - Stock Price Chart
TickerCBAN [NASD, RUT]
CompanyColony Bankcorp, Inc.
CountryUSA
IndustryBanks - Regional
Market Cap271.30MEPS (ttm)1.26
P/E12.22EPS this Y2.71%
Forward P/E10.20EPS next Y14.34%
PEG1.75EPS past 5Y-2.38%
P/S1.59EPS next 5Y7.00%
P/B1.02EPS Q/Q3.42%
Dividend2.91%Sales Q/Q7.85%
Insider Own12.86%Inst Own47.61%
Insider Trans0.10%Inst Trans-0.33%
Short Float0.41%EarningsJul 24/a
Analyst Recom2.00Target Price14.62
Avg Volume45.37K52W Range9.35 - 14.38
Colony Bankcorp, Inc. is a bank holding company, which engages in the stockholder and investor relations functions through its subsidiary, Colony Bank. It operates through the following segments: Banking Division, Mortgage Division, and Small Business Specialty Lending Division. The Banking Division segment offers full service financial services including commercial loans, consumer loans and deposit accounts. The Mortgage Division segment consists of sales and servicing of one-to-four family residential mortgage loans. The Small Business Specialty Lending Division segment focuses on the selling and servicing of SBA and USDA government guaranteed loans. The company was founded on November 8, 1982 and is headquartered in Fitzgerald, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bateman Leonard H JREVP & Chief Credit OfficerFeb 23 '24Buy11.111,00911,21410,440Feb 26 04:54 PM
Shelnutt DerekCFOFeb 14 '24Buy11.081001,1088,039Feb 14 04:32 PM
Fountain T HeathPresident and CEOFeb 02 '24Buy11.948009,55252,888Feb 05 04:13 PM
Fountain T HeathPresident and CEOFeb 02 '24Buy11.924004,76922,248Feb 05 04:13 PM
Wyatt HaroldDirectorDec 15 '23Sale12.581,00012,5802,600Dec 18 04:20 PM
FBIN - Fortune Brands Innovations Inc - Stock Price Chart
TickerFBIN [NYSE]
CompanyFortune Brands Innovations Inc
CountryUSA
IndustryBuilding Products & Equipment
Market Cap9.85BEPS (ttm)3.53
P/E22.30EPS this Y9.50%
Forward P/E16.61EPS next Y10.71%
PEG2.96EPS past 5Y3.55%
P/S2.06EPS next 5Y7.53%
P/B4.34EPS Q/Q32.92%
Dividend1.26%Sales Q/Q6.56%
Insider Own0.52%Inst Own93.36%
Insider Trans-3.20%Inst Trans0.74%
Short Float2.37%EarningsJul 25/a
Analyst Recom2.37Target Price85.53
Avg Volume1.39M52W Range54.10 - 84.92
Fortune Brands Innovations, Inc. is an innovation and channel leader focused on supercharged categories in the home products, security, and commercial building markets. Its brands include Moen, House of Rohl, Aqualisa, Emtek, Therma-Tru, Larson, Fiberon, Master Lock, SentrySafe, Yale and August. The company was founded on June 9, 1988 and is headquartered in Deerfield, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WATERS RONALD VDirectorMar 11 '24Sale81.102,000162,2042,435Mar 12 05:35 PM
PHYFER CHERI MEVP, Group PresidentMar 05 '24Option Exercise41.428,441349,62684,448Mar 06 05:08 PM
PHYFER CHERI MEVP, Group PresidentMar 05 '24Sale81.6019,5301,593,67164,918Mar 06 05:08 PM
MSTR - Microstrategy Inc. - Stock Price Chart
TickerMSTR [NASD]
CompanyMicrostrategy Inc.
CountryUSA
IndustrySoftware - Application
Market Cap31.09BEPS (ttm)-6.70
P/E-EPS this Y-121.01%
Forward P/E-EPS next Y48.25%
PEG-EPS past 5Y68.04%
P/S63.51EPS next 5Y10.00%
P/B12.89EPS Q/Q-109.72%
Dividend-Sales Q/Q-5.47%
Insider Own11.13%Inst Own55.57%
Insider Trans-16.95%Inst Trans-3.18%
Short Float15.28%EarningsAug 01/a
Analyst Recom1.38Target Price1959.82
Avg Volume1.33M52W Range307.11 - 1999.99
MicroStrategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Le PhongPresident & CEOJun 17 '24Sale1441.81590850,6681,267Jun 20 09:28 PM
Kang AndrewSEVP & CFOJun 17 '24Sale1441.81209301,3381,778Jun 20 09:22 PM
Shao Wei-MingSEVP & General CounselJun 17 '24Sale1441.81190273,944646Jun 20 09:19 PM
Montgomery JeanineSVP & CAOJun 17 '24Sale1441.813854,789567Jun 20 09:25 PM
SAYLOR MICHAEL JExecutive ChairmanApr 25 '24Option Exercise121.435,000607,1505,000Apr 26 04:11 PM
CSTL - Castle Biosciences Inc - Stock Price Chart
TickerCSTL [NASD, RUT]
CompanyCastle Biosciences Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap581.47MEPS (ttm)-1.15
P/E-EPS this Y24.63%
Forward P/E-EPS next Y-18.71%
PEG-EPS past 5Y-28.57%
P/S2.32EPS next 5Y-
P/B1.44EPS Q/Q91.60%
Dividend-Sales Q/Q73.59%
Insider Own9.15%Inst Own87.83%
Insider Trans-5.41%Inst Trans-2.02%
Short Float7.22%EarningsAug 05/a
Analyst Recom1.11Target Price34.33
Avg Volume315.32K52W Range12.07 - 25.91
Jul-22-24 07:00AM Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma (Business Wire)
Jul-15-24 07:00AM Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 (Business Wire)
Jul-12-24 12:00PM All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 07:00AM Castle Biosciences Honored with Top Workplaces Awards (Business Wire) +5.78%
Jun-24-24 07:00AM Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences TissueCypher Test (Business Wire)
Jun-20-24 07:00AM Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-14-24 04:30PM Castle Biosciences Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year 2024 Gulf South Award Winner (Business Wire)
Jun-13-24 09:40AM Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year? (Zacks)
May-30-24 04:30PM Castle Biosciences to Present New Data at 2024 ASCO Annual Meeting Highlighting Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance (Business Wire)
May-29-24 04:30PM New Publication Shows DecisionDx-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis (Business Wire)
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Oelschlager Kristen MChief Operating OfficerJul 01 '24Sale21.222,79359,279148,618Jul 03 04:15 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerJun 03 '24Sale23.403,96892,8578,525Jun 05 05:23 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerJun 03 '24Sale23.402,36855,41657,893Jun 05 05:23 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerMay 14 '24Sale24.273,96896,2908,911May 16 04:20 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerMay 14 '24Sale24.272,36857,46360,261May 16 04:20 PM
SERV - Serve Robotics Inc - Stock Price Chart
TickerSERV [NASD]
CompanyServe Robotics Inc
CountryUSA
IndustrySpecialty Industrial Machinery
Market Cap490.46MEPS (ttm)-0.78
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S441.86EPS next 5Y19.00%
P/B-EPS Q/Q-75.92%
Dividend-Sales Q/Q2251.96%
Insider Own36.70%Inst Own0.29%
Insider Trans0.46%Inst Trans-
Short Float7.16%EarningsMay 29
Analyst Recom1.00Target Price8.00
Avg Volume9.22M52W Range1.77 - 37.00
Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NVIDIA CORP10% OwnerJul 31 '23Buy4.0062,500250,0002,676,904Jul 18 05:20 PM
STOK - Stoke Therapeutics Inc - Stock Price Chart
TickerSTOK [NASD, RUT]
CompanyStoke Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap826.62MEPS (ttm)-2.42
P/E-EPS this Y4.36%
Forward P/E-EPS next Y-11.83%
PEG-EPS past 5Y-44.06%
P/S105.44EPS next 5Y-
P/B5.25EPS Q/Q-7.60%
Dividend-Sales Q/Q-18.17%
Insider Own25.38%Inst Own79.29%
Insider Trans-22.57%Inst Trans-1.58%
Short Float26.48%EarningsMay 06/b
Analyst Recom1.22Target Price22.14
Avg Volume772.56K52W Range3.35 - 17.58
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nash Huw M.Chief Business OfficerJul 02 '24Sale13.112,50032,7790Jul 03 04:13 PM
Ticho BarryCHIEF MEDICAL OFFICERJul 01 '24Option Exercise0.6010,0006,00012,485Jul 03 04:11 PM
Ticho BarryCHIEF MEDICAL OFFICERJul 01 '24Sale13.7510,000137,4582,485Jul 03 04:11 PM
Ticho BarryCHIEF MEDICAL OFFICERJun 03 '24Option Exercise0.6010,0006,00012,485Jun 05 04:18 PM
Ticho BarryCHIEF MEDICAL OFFICERJun 03 '24Sale15.2210,000152,1852,485Jun 05 04:18 PM
INBK - First Internet Bancorp - Stock Price Chart
TickerINBK [NASD, RUT]
CompanyFirst Internet Bancorp
CountryUSA
IndustryBanks - Regional
Market Cap338.61MEPS (ttm)2.12
P/E18.42EPS this Y66.23%
Forward P/E9.31EPS next Y38.00%
PEG-EPS past 5Y-16.23%
P/S1.12EPS next 5Y-
P/B0.91EPS Q/Q53.10%
Dividend0.61%Sales Q/Q28.13%
Insider Own15.07%Inst Own61.08%
Insider Trans0.00%Inst Trans-1.60%
Short Float2.07%EarningsJul 24/a
Analyst Recom2.20Target Price40.60
Avg Volume66.19K52W Range14.11 - 37.69
TodayReiterated Hovde Group Outperform $38 → $44
First Internet Bancorp engages in the provision of online commercial and retail banking products and services. It offers first-lien residential mortgage loans, consumer loans and credit cards & CRE loans in Indiana and other parts of the midwest in the form of office, retail, industrial, and multifamily loans, with credit tenant lease financing. The company was founded on September 15, 2005 and is headquartered in Indianapolis, IN.
CHRS - Coherus Biosciences Inc - Stock Price Chart
TickerCHRS [NASD, RUT]
CompanyCoherus Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap197.34MEPS (ttm)-0.79
P/E-EPS this Y102.03%
Forward P/E-EPS next Y-757.35%
PEG-EPS past 5Y4.73%
P/S0.65EPS next 5Y-
P/B-EPS Q/Q185.78%
Dividend-Sales Q/Q137.58%
Insider Own4.04%Inst Own69.92%
Insider Trans0.00%Inst Trans-1.48%
Short Float20.91%EarningsMay 09/a
Analyst Recom1.75Target Price9.00
Avg Volume1.66M52W Range1.25 - 5.47
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wahlstrom MatsDirectorFeb 01 '24Option Exercise1.6759,988100,00099,988Feb 05 07:03 PM
Lanfear Dennis MPresident & CEONov 22 '23Option Exercise1.42299,940425,015954,793Nov 24 04:04 PM
Lanfear Dennis MPresident & CEONov 22 '23Sale2.02223,100449,770731,693Nov 24 04:04 PM
167891011121314151620